The introduction of anticardiolipin antibody (aCL) assay, described in 1983, was able to focus much attention on the study of patients suffering from thrombosis, repeated fetal loss and thrombocytopenia, and allowing the identification of the so called antiphospholipid syndrome (APS). The identification of β2 glycoprotein I (β22GPI) as an essential component of the antigenic complex recognized by aCL suggested that this molecule could be a direct target of the antibody response. Since then, different groups have described ELISAs for the detection of anti β2GPI antibodies, applied to the clinical evaluation of patients with APS, and showing an overall better specificity. Recently, anti β2GPI were also shown to bind apoptotic bodies resulting in an alteration of their physiological clearance with the triggering of TNFα release. This observation suggests that anti β2GPI may also modify the immunogenicity of apoptotic bodies and of the autoantigens that they contain.
HarrisEN. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.Lancet1983; 2: 1211–1214.
LoizouS. Measurement of anticardiolipin antibodies by an enzyme linked immunosorbent assay (ELISA): standardization and quantitation of result.Clin Exp Immunol1985; 62: 738–745.
7.
GinsbergJS. Antiphospholipid antibodies and venous thromboembolism.Blood1995; 86: 3685–3691.
8.
HorbachDA. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with Systemic Lupus Erythematosus.Thromb Haemost1996; 76: 916–924.
9.
RoubeyRAS.Antiphospholipid antibody syndrome. In: KoopmanWJ (eds) Arthritis and Allied Conditions: a Textbook of Rheumatology13th ed.Lea & Febiger: Philadelphia, 1997, 1393–1406.
10.
HarrisEN, GharaviAE, PatelSP, HughesGRV.Evaluation of the anticardiolipin antibody test: Report of a standardization workshop held in April 1986.Clin Exp Immunol1987; 68: 215–222.
11.
GalliM. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor.Lancet1990; 335: 1544–1547.
12.
McNeilHP, SimpsonRJ, ChestermanCN, KrilisSA.Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2glycoprotein I (apolipoprotein H).Proc Natl Acad Sci USA1990; 87: 4120–4124.
13.
ArvieuxJ, RousselB, JacobMC, ColombMG.Mesurement of antiphospholipid antibodies by ELISA using using b2-glicoprotein I as antigen.J Immunol Methods1991; 143: 223–229.
14.
ViardJP, AmouraZ, BachJF.Association of anti b2-glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus.Am J Med1992; 93: 181–186.
15.
RoubeyRAS, MaldonadoMA, ByrdSN, WinfieldJB.Elisa for autoantibodies to β2-glycoprotein I: comparison with a standard anticardiolipin assay.Arthritis Rheum1994; 37: S298. (Abstr).
16.
BalestrieriG. Anti-β2-glycoprotein I: a marker of antiphospholipid syndrome?Lupus1995; 4: 122–130.
17.
MatsuuraE. Anticardiolipin antibodies recognize β2 glycoprotein I structure altered by interacting with an oxygen modified solid phase surface.J Exp Med1994; 179: 457–462.
18.
RoubeyRAS, EisenbergRA, HarperMF, WinfieldJB: ‘Anticardiolipin’ autoantibodies recognize β2-Glycoprotein I in the absence of phospholipid: importance of antigen density and bivalent binding.J Immunol1995; 154: 954–960.
19.
TincaniA. The Anti Beta 2 Glycoprotein I activity in human antiphospholipid syndrome sera is due to monorcactive low affinity autoantibodies directed to epitopes located on native Beta 2 Glycoprotein I and preserved during species’ evolution.J Immunol1996; 157: 5732–5738.
20.
RoubeyRAS.Immunology of the antiphospholipid antibody syndrome.Arthritis Rheum1996; 39: 1444–1454.
CabidesJ, CabralA, Alarcon-SegoviaD.Clinical manifestation of antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti β2glycoprotein I than with antiphospholipid antibosies.J Rheumatol1995; 22: 1899–1906.
23.
AmegualO. Specificity of ELISA for antibody to b2-glycoprotein I in patients with antiphospholipid syndrome.Br J Rheumatol1996; 35: 1239–1243.
24.
MatsuuraE. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.Lancet1990; 336: 177–178.
25.
HojnikM. Anticardiolipin antibodies in infections are heterogeneous in their dependency on β2-glycoprotein I: analysis of anticardiolipin antibodies in leprosy.Lupus1994; 3: 515–518.
26.
PriceBE. Anti-phospholipid antibodies bind to apoptotic but not to viable, thymocytes in a β2-glicoprotein I-dependent manner.J Immunol1996; 157: 2201–2208.
27.
ManfrediA. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies.Arthritis Rheum1998; 41: 205–214.
28.
ManfrediA. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of β2-Glycoprotein I.Arthritis Rheum1998; 41: 215–223.
29.
MoreJE, LutzWB.The natural history of systemic lupus erythematosus: an approach to its study through chronic biologic false positive reactors.J Chronic Dis1955; 1: 297–316.
